Research programme: alpha-2C adrenoceptor agonists - AstraZeneca

Drug Profile

Research programme: alpha-2C adrenoceptor agonists - AstraZeneca

Alternative Names: Alpha-2C adrenoceptor agonists research programme - AstraZeneca

Latest Information Update: 20 Oct 2008

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Alpha 2c adrenoceptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 04 May 2000 New profile
  • 04 May 2000 Preclinical development for Pain in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top